Trial Of PF-00299804 In Patients With Advanced Refractory Lung Cancer

• Status: Completed
• Trial end date: 2014-07-17
• Target enrollment: 0
• Participant gender: All

Summary

To assess the safety and efficacy of PF-00299804 in patients with advanced lung cancer.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Pfizer

Criteria

Inclusion Criteria:

• Advanced NSCLC

• Prior treatment with and failure of at least one regimen of chemotherapy and erlotinib or gefitinib

• Prior treatment with no more than two chemotherapy regimens, including adjuvant treatment

• Measurable disease

Exclusion Criteria:

• Chemotherapy, radiotherapy, biological or investigational agents within 4 weeks of baseline disease assessment

• Patients who lack of tolerance of erlotinib therapy

• Patients with known brain Metastases

• Patients with demonstrated history of or presence of interstitial lung disease.